HCPCS code Q4170: Cygnus skin substitute billing guide

HCPCS code Q4170 is the Level II billing code for Cygnus, an amniotic membrane skin substitute from Vivex Biologics. It is reported per square centimeter of wound area.

Medicare no longer prices it on Average Sales Price. Since January 1, 2026, CMS pays skin substitute products as incident-to supplies at a flat per-square-centimeter rate. That comes to roughly $127.28 under the physician fee schedule and $127.14 under the OPPS, where Cygnus sits in APC 6002.

This guide covers the 2026 payment rules, coverage criteria, ICD-10-CM pairings, documentation, and the billing sequence for wound care claims that involve skin substitutes.

Found our content helpful?

Key takeaways

HCPCS code Q4170 describes Cygnus from Vivex Biologics, an amniotic membrane skin substitute billed per square centimeter of wound area

From January 1, 2026, CMS pays Q4170 as an incident-to supply at a flat rate rather than on Average Sales Price

The 2026 rate runs to roughly $127.28 per cm² under the physician fee schedule and $127.14 per cm² under the OPPS

Cygnus is regulated as a Section 361 HCT/P, so it lands in APC 6002 and keeps no ASP-based pricing

No national LCD covers skin substitutes. Novitas applies LCD L35041, First Coast applies L36377, and CGS applies L36690

Pair Q4170 with a CPT application code from 15271 to 15278. Pabau’s claims management software flags a missing one before submission

What is HCPCS code Q4170?

HCPCS code Q4170 is the Healthcare Common Procedure Coding System Level II code for Cygnus skin substitute, billed per square centimeter of treated wound area. Cygnus is a human amniotic membrane product manufactured by Vivex Biologics. It is applied to chronic, non-healing wounds, most often diabetic foot ulcers and venous leg ulcers.

The “Q” prefix marks it as a temporary HCPCS code assigned by the Centers for Medicare and Medicaid Services (CMS). Q4170 remains active for 2026. CMS now treats these product codes as add-on codes reported alongside the application procedure, rather than as standalone biologicals.

The unit of measure decides the payment. Billers calculate the wound surface area in square centimeters, length multiplied by width, and report that figure as the unit quantity. Under the 2026 flat rate, that number is the only variable left in the price.

Cygnus skin substitute: Product overview for billers

Cygnus is a dehydrated human amnion membrane allograft from Vivex Biologics. Knowing the product matters for billing, because its FDA regulatory category now sets its payment group. Cygnus is regulated under Section 361 of the PHS Act, which places it in APC 6002 for 2026.

• Tissue type: Dehydrated human amniotic membrane, preserved for ambient storage rather than cryopreserved
• Regulatory pathway: Section 361 HCT/P, so the Section 351 ASP exception does not reach it
• Intended use: Applied to chronic, non-healing wounds to support tissue regeneration; not indicated for infected wounds
• Primary indications: Diabetic foot ulcers, venous leg ulcers, and other chronic lower extremity ulcers
• Application method: Placed on a debrided wound bed and trimmed to fit; bill the square centimeters applied, not the sheet size
• Storage and handling: Ambient storage per the manufacturer’s specification, with lot number and expiration date recorded in the patient chart

Wound care practices that stock several skin substitutes need inventory tracked by lot number against the patient record. When product usage is logged against the encounter, the lot on the chart matches the lot on the claim.

Q4170 fee schedule and Medicare reimbursement rates

Medicare no longer pays Q4170 on Average Sales Price. Since January 1, 2026, CMS treats skin substitute products as incident-to supplies furnished with a covered application procedure. Payment runs through the physician fee schedule in the non-facility setting and through the OPPS in hospital outpatient departments.

The rate is site-neutral and product-neutral. CMS set roughly $127.28 per square centimeter under the physician fee schedule, and that figure is geographically adjusted. The OPPS rate is $127.14 per square centimeter, with no geographic adjustment applied.

Cygnus no longer carries a product-specific price. Every product in the same FDA category is paid the same amount per square centimeter, whatever the invoice says. Wastage is not separately payable, so discarded product cannot be billed with a JW modifier.

Place of service still decides which system pays. A physician office bills Q4170 under the physician fee schedule. A hospital outpatient department bills under the OPPS. The two rates sit close together, but the wrong place-of-service code remains an audit trigger.

Check the current figure before you bill, since CMS issues technical corrections during the year. The CMS Physician Fee Schedule lookup tool returns the rate for your MAC jurisdiction and place-of-service indicator. Building a quarterly rate check into your billing calendar keeps fee estimates honest.

What replaced the ASP and high-cost/low-cost methodology

Through December 31, 2025, Q4170 was priced from the manufacturer’s Average Sales Price and sorted into a high-cost or low-cost OPPS tier.

The CY2026 OPPS final rule removed both. CMS also deleted codes C5271 through C5278 on December 31, 2025. The old and new rules differ on every line a biller touches.

Products are now grouped by FDA pathway instead of by cost. CMS created three new APCs, each carrying status indicator S1, and set one payment rate across all three for the first year.

CMS took the highest weighted ASP across the three groups, found in APC 6002, and applied that single rate to all of them. Only biologics licensed under Section 351 of the PHS Act kept ASP methodology. Cygnus is a 361 HCT/P, so it does not qualify for that exception.

Sheet-form products stay unpackaged and separately paid under the OPPS. Q4170 therefore lands in APC 6002 rather than being folded into payment for the application procedure. The CY2026 OPPS final rule sets out this grouping.

Facility vs non-facility billing for Q4170

Place of service (POS) determines which payment system governs the claim, and which bill type and revenue codes apply. Under the 2026 rules the choice no longer changes the price very much, but it still changes the paperwork. Billing POS 11 for a procedure performed in a hospital outpatient department is an overpayment risk.

In a hospital outpatient department the facility bills the product and the physician bills only the professional component. Confirm with the facility billing team how that split is handled, so the product is not reported twice.

Where a course of treatment spans several sessions, each date of service needs its own claim with the POS that applied that day.

CPT application codes to bill alongside Q4170

Q4170 is a product code and cannot stand alone on a claim. In the Novitas jurisdictions the controlling policy is billing article A54117. Its full title is Billing and Coding: Application of Bioengineered Skin Substitutes to Lower Extremity Chronic Non-Healing Wounds.

The article requires a companion CPT application code from the 15271-15278 series, and the First Coast and CGS articles say the same. Submitting the product without that code is the most common denial here.

Codes 15273, 15274, 15277 and 15278 are not pediatric codes. They apply to any patient whose total wound surface area reaches 100 sq cm or more. The body-percentage wording in the descriptor is an alternate measure for infants and children, not an age restriction.

ICD-10-CM diagnosis codes covered with Q4170

Every Q4170 claim needs at least one covered ICD-10-CM diagnosis code. Covered lists are jurisdictional rather than national. Each MAC’s billing article carries its own list of ICD-10-CM codes that support a skin substitute application. Check the patient’s diagnosis against the applicable list before the product is opened.

Most L97 and L98 codes require a laterality and severity qualifier. The code selected has to match the wound’s documented location and current clinical status. Reaching for an unspecified code when a specific one exists raises denial risk and invites review. The AAPC HCPCS code lookup is a useful cross-reference for Q-code and diagnosis pairings.

Medicare coverage criteria for Q4170

No national coverage determination governs skin substitutes, so coverage depends on your Medicare Administrative Contractor. Novitas applies LCD L35041 with billing article A54117. First Coast Service Options applies LCD L36377 with article A57680, and CGS applies LCD L36690 with article A56696.

Palmetto GBA, NGS, WPS and Noridian carry no skin substitute LCD and review these claims case by case. A harmonized set of DFU and VLU policies was withdrawn on December 24, 2025, before it took effect. Confirm your own jurisdiction’s position before the product goes on the wound, and verify the patient’s benefits first.

Where one of those LCDs applies, the criteria below generally have to be met before Q4170 is billed:

• Wound type: A diabetic foot ulcer or venous leg ulcer that has failed to respond to conventional wound care
• Duration: The wound has been present and actively treated for at least 30 days before the first application
• Prior treatment failure: Records showing debridement, compression, offloading or moist dressings were tried and did not close the wound
• Wound size: Dimensions measured and documented at the time of application, since the units billed follow the measurement
• Physician involvement: A licensed physician orders and supervises the application; NPs and PAs may apply within state scope-of-practice rules
• Medical necessity: A narrative in the record explaining why this product suits this patient at this point in treatment

Payer-specific coverage notes

Commercial payers run their own skin substitute policies. Those often differ from the MAC policies on covered diagnoses and on the number of applications allowed per wound episode. Prior authorization is payer-specific too. Some MACs and commercial plans require it, others do not.

Medicare also limits applications per wound episode. Going past that limit without documented healing progress is one of the most reliable ways to trigger a denial. Check the payer’s current policy before each application episode rather than at the end of it.

Documentation requirements for billing Q4170

Thin documentation is the main reason skin substitute claims fail on post-payment audit. Each MAC’s billing article sets out what the record needs before and at the time of each application. Compliance requirements for these Q-codes run tighter than for most supply codes, because payers watch this category closely.

• Wound measurements: Length by width in centimeters, recorded on the date of application; this sets the unit count billed
• Wound duration: The date the wound was first identified, plus notes showing at least 30 days of active treatment
• Prior treatment record: Debridement notes, dressing change records, and offloading or compression compliance from the period before the application
• Medical necessity statement: A physician note explaining why Cygnus was selected and why continued conventional care would not close the wound
• Product application record: Lot number, expiration date, graft size, and any trimming; the billed square centimeters cannot exceed what was applied
• Wound photographs: Pre- and post-application images; several MACs require them and they carry most of the weight in an audit
• Physician order: A signed order naming the specific product and the application date
• Record retention: Files kept for the full retention period your state and HIPAA require, with the application records intact

How to bill Q4170: Step-by-step billing guidelines

Billing Q4170 correctly comes down to six steps, from wound measurement through claim submission. A mistake at any one of them produces a denial, an underpayment, or an audit finding. Most of the manual arithmetic disappears in error-checking claims software that understands HCPCS Q-code workflows.

1. Measure the wound: Record length by width in centimeters at the time of application and multiply for the surface area. Document it in the chart immediately, because the units billed have to match it
2. Confirm a covered diagnosis: Check the patient’s ICD-10-CM code against the covered list that applies in your jurisdiction. Select the most specific code available for laterality, severity and location
3. Add the application code: Pair Q4170 with the correct CPT code from 15271 to 15278, chosen by body region and total wound area. The product code alone will be denied
4. Select place of service: Use POS 11 for the office, POS 22 for hospital outpatient, and POS 24 for an ASC. That choice decides whether the PFS or the OPPS rate applies
5. Check prior authorization: Some commercial payers and some MACs require it for skin substitutes. Confirm before the procedure, since authorization obtained afterward is rarely honored
6. Build the superbill and submit: Carry Q4170 with the unit count in sq cm and the covered diagnosis codes. Add the application CPT code, the provider NPI and the date of service. A complete superbill transmits cleanly to the clearinghouse

Verify the claim before transmission. Missing fields, mismatched dates and absent modifiers cause most technical rejections. A pre-submission check catches them earlier than any appeal.

Coverage policy updates: Q4170 from 2023 through 2026

The skin substitute landscape tightened steadily from 2023, then changed shape entirely in January 2026. Medicare Part B spending on these products rose sharply between 2022 and 2024.

CMS responded first with documentation scrutiny, then with a new payment method. A practice working from 2022 assumptions is now wrong on both coverage and price.

What changed between 2023 and 2025

• Stricter prior treatment documentation: MACs began expecting progress notes from each wound care visit in the 30-day window, rather than a summary statement
• Measurement at every visit: Several MACs clarified that wound measurements belong in the record at each visit, not only on the application date
• Application frequency limits: CMS and the MACs tightened the number of applications allowed per wound episode without documented healing progress
• LCD revisions: Palmetto GBA, Novitas, CGS and others revised or withdrew skin substitute policies on different schedules through 2023 to 2025
• Product-specific coverage decisions: Individual products gained or lost coverage during those LCD cycles, so covered product lists moved year to year

The January 2026 payment overhaul

The CY2026 rules rewrote skin substitute payment rather than adjusting it. CMS finalized the change in the CY2026 physician fee schedule and OPPS final rules, CMS-1832-F and CMS-1834-FC. The operating instructions arrived in MLN change request MM14361. All of it took effect on January 1, 2026.

• Incident-to supply payment: CMS now pays skin substitute products as supplies furnished with a covered application procedure, under both the PFS and the OPPS
• One flat rate: Roughly $127.28 per square centimeter under the PFS, geographically adjusted, and $127.14 under the OPPS, where no geographic adjustment applies
• ASP pricing retired: Product-specific Average Sales Price pricing ended for Q4170. Only biologics licensed under Section 351 of the PHS Act kept ASP methodology
• Three new APCs: CMS created APC 6000 for PMA products, APC 6001 for 510(k) products, and APC 6002 for Section 361 HCT/Ps. Cygnus sits in APC 6002
• High-cost and low-cost tiers gone: The old OPPS grouping was eliminated and codes C5271 through C5278 were deleted on December 31, 2025
• No payment for wastage: Discarded product is not separately payable, so trimmed material cannot be billed with a JW modifier
• Q-code status unchanged: Q4170 remains an active 2026 code for Cygnus, so verify it against the current CMS HCPCS code files before billing
• Coverage did not follow payment: The withdrawn DFU and VLU policies left coverage in the hands of individual MACs, even as pricing became national

The practical effect is that the invoice price of Cygnus no longer drives the reimbursement. Practices that bought on acquisition cost and billed on ASP need to rebuild their margin assumptions from the flat rate up.

Related HCPCS codes for skin substitutes

Q4170 sits inside a large family of skin substitute Q-codes, all listed in the HCPCS code index. Each code names a specific product from a specific manufacturer. Billing the wrong Q-code is a compliance problem rather than a clerical one, and the 2026 flat rate removes any pricing advantage from doing it.

Confirm the Q-code from the product label and lot number in the clinical record. If a different product is substituted at the time of application, the claim has to name the product that went on the wound. Never swap one Q-code for another to reach a better rate, since that is upcoding and creates false claims exposure.

Common billing errors and denial reasons for Q4170

Q4170 denies more often than most HCPCS codes, because payers audit this category closely. Good denial management starts by preventing the patterns below rather than appealing them afterward.

Read the remittance advice adjustment reason code before choosing between an appeal and a corrected claim. Many skin substitute denials clear with additional documentation, which is the fastest route when the records were complete from the start.

How Pabau supports wound care billing workflows

A wound care practice applying skin substitutes has to keep measurements, companion codes, product lot numbers and prior treatment notes connected across weeks of visits. Under the 2026 flat rate, the measurement in the chart is the number that gets paid. Any drift between the note and the claim costs money.

Practice management software like Pabau holds those pieces in one patient record. Pabau’s claims management tools track what a Q4170 claim needs, from the wound measurement through to submission. Because the treatment note feeds the charge, a missing application code gets caught before the claim goes out.

Inventory tracked by lot number sits beside the encounter, so the product on the chart is the product on the claim. Your team spends its time on wounds instead of reconciling two systems at month end.

Simplify wound care billing with Pabau

Pabau’s claims management tools support HCPCS Q-code workflows, superbill generation, and payer-specific billing rules. Your wound care practice spends less time fixing claims and more time treating patients.

Book a demo

Conclusion

The 2026 rules moved the risk on a Q4170 claim from pricing to measurement. When every square centimeter pays the same fixed amount, the figure in the wound note becomes the figure on the remittance. Tightening measurement discipline pays back faster than any appeal your team writes.

Coverage deserves the same caution. Pricing went national in January 2026, but coverage did not. Until CMS replaces the withdrawn DFU and VLU policies, your own MAC decides whether the application is payable at all.

Get those two right and most of the rework this code generates disappears. Book a demo to see how Pabau keeps wound measurements, companion codes and claim submission in one workflow.

Continue your research

Need to understand how clean claims reduce skin substitute denials? Clean claim best practices covers the documentation elements that decide first-pass claim acceptance.

Want to see how the revenue cycle connects to skin substitute reimbursement? Revenue cycle management explained covers the process from eligibility through payment posting.

Frequently asked questions